ClinicalTrials.gg
Not yet recruitingNCT07634354SAJIUpdated Jun 8, 2026

Sarcopenia and Juvenile Idiopathic Arthritis

An interventional study of Sarcopenia screening assessment in Juvenile Idiopathic Arthritis, sponsored by CHU de Reims. Not yet recruiting at 1 site in France. Open to participants aged 15 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by CHU de Reims · Not applicable, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
15 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Arthritis, Juvenile with a site in France — 18 open to participants now, 21 under way, 9 of them phase 3. Arthritis, Juvenile · France.

Planned enrollment
8th of 50
200 · median 61
Started
2026
with 3 others
No phase
13 of 71
4 open now
Primary completion
2027-10
later than 9 of 20 live
Registered
70th of 71
by date

Among the 71 studies in Arthritis, Juvenile with a site in France, this one is the 8th largest by planned enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2026, is one of 13 with no phase, reaches primary completion later than 9 of the 20 other live ones, and was the 70th registered.

Arthritis, Juvenile

367 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

18 of the 71 studies in Arthritis, Juvenile with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: 15 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Arthritis, Juvenile with a site in France, or all of them as a file.
02

Study summary

Juvenile idiopathic arthritis (JIA) is a rare chronic inflammatory rheumatic disease that begins during childhood and may persist into adulthood in many patients. In addition to joint pain, swelling, and long-term articular damage, chronic inflammatory diseases may also be associated with early sarcopenia, defined as a loss of muscle strength and muscle mass. While this association has been described in adult inflammatory rheumatic diseases, it has not been well studied in patients with JIA.

The aim of this study is to screen for sarcopenia in adolescents and adults with JIA in France. Sarcopenia will be assessed using validated questionnaires, hand grip strength measured with a Jamar dynamometer, and body composition measured by dual-energy X-ray absorptiometry (DEXA). Completion of validated questionnaires will assess nutritional status, fatigue, physical activity, and functional impact. Socio-demographic and clinical data will also be collected from medical records.

This multicenter cross-sectional study will be conducted between June 2026 and October 2027 in 11 French hospitals. Eligible participants are patients aged 15 to 40 years with JIA diagnosed according to ILAR criteria and followed in a French hospital.

This study will provide the first estimate of sarcopenia prevalence among patients with JIA in France. It will also help identify factors associated with sarcopenia and its impact on daily functioning and quality of life. In the longer term, the findings may help clinicians better identify patients at risk and support earlier management focused on disease control, physical activity, and nutritional care.

Read the detailed description

This is a national multicenter cross-sectional study conducted in 11 French hospitals between June 2026 and October 2027. The study aims to assess sarcopenia in adolescents and adults with juvenile idiopathic arthritis (JIA) during a routine rheumatology follow-up visit.

After receiving study information and providing informed consent (with parental/legal guardian consent for minors, according to applicable regulations), participants will undergo a standardized single study assessment during routine care. This assessment will include measurement of hand grip strength using a Jamar dynamometer, whole-body dual-energy X-ray absorptiometry (DEXA) for body composition and appendicular lean mass evaluation, and completion of validated questionnaires addressing nutritional status, fatigue, physical activity, and functional impact. Additional socio-demographic and clinical data related to JIA history, disease characteristics, and treatments will be collected from medical records.

The study is designed to estimate the prevalence of sarcopenia in patients with JIA in France and to explore factors associated with sarcopenia and its functional impact. If sarcopenia is identified, additional management may be proposed by the treating physician as part of usual care.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Keywords

  • Juvenile idiopathic arthritis
  • Sarcopenia
04

Who can participate

Ages eligible
15 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients followed in French hospitals participating in the study for juvenile idiopathic arthritis, all forms combined, diagnosed according to the ILAR criteria defined in Edmonton in 2001
  • Patients aged 15 to 40 years
  • Affiliated to social security
  • Agreeing to participate in the study and having given their written consent (signed consent form).

In the case of a minor patient, the consent of the patient and their legal guardians is required.

Exclusion criteria

exclusion criteria :

  • Patient under legal guardianship
  • Patient not covered by social security
  • Pregnant woman
  • Inability to perform a functional test required by the study (grip test or whole-body DEXA scan)
  • Inability to understand the questionnaires
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    Patients with juvenile idiopathic arthritis

    Single group of adolescents and adults with juvenile idiopathic arthritis undergoing a standardized sarcopenia screening assessment at inclusion.

    Other: Sarcopenia screening assessment

Interventions

  • OtherSarcopenia screening assessment

    Participants will undergo a standardized single-visit assessment including hand grip strength measurement, whole-body DEXA scan for body composition, validated questionnaires, and collection of socio-demographic and clinical data from medical records.

06

What researchers measure

Primary outcomes

  1. Sarcopenia

    A cross-sectional assessment of sarcopenia for each included patient will be performed at a participating hospital center: Performance of a hand grip test using a hand dynamometer (3 consecutive measurements on the dominant hand) and a whole-body DEXA scan with measurement of the appendiceal mass index Confirmation by the best grip test value \< -2 SD according to the patient's age and sex on the reference curves associated with a pathological whole-body DEXA (appendiceal mass index ≤ 7 kg/m2 for men, ≤ 5.5 kg/m2 for women)

    Time frame: Day 1

Secondary outcomes

  1. Fatigue assessed by FACIT-F

    Fatigue assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire

    Time frame: Day 1

  2. Physical activity assessed by IPAQ

    Physical activity assessed using the International Physical Activity Questionnaire (IPAQ)

    Time frame: Day 1

  3. Functional disability assessed by HAQ-DI

    Functional disability assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI).

    Time frame: Day 1

  4. Health-related quality of life assessed by SF-12

    Health-related quality of life assessed using the 12-Item Short Form Health Survey (SF-12).

    Time frame: Day 1

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Oct 2027, 16 months later.

Of 53 non-industry interventional studies with no phase under Arthritis, Juvenile, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's planned 16 months is above that.

Counting every sponsor, half of 56 studies reached it within 14 months; a quarter within 8 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 8, 2026
StartEst.
Jun 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07634354
Lead sponsor
CHU de Reims
Responsible party
Sponsor
First posted
Jun 8, 2026
Start date
Jun 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Ambre HITTINGER-ROUX
Contact
ahittinger-roux@chu-reims.fr
03 10 73 67 07 ext. 0033
Jean-Hugues SALMON
Contact
jhsalmon@chu-reims.fr
03 26 78 44 21 ext. 0033

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion